Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143476 · ClinicalTrials.gov registry record
Serum-Protein-Based Indices for the Progression of Fracture Healing and Nonunion
A clinical trial of Humerus Fractures, sponsored by Major Extremity Trauma Research Consortium.
- Completed
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT05143476: Completed study of Humerus Fractures, sponsored by Major Extremity Trauma Research Consortium.
NCT05143476 is a study of Humerus Fractures that has completed, run by Major Extremity Trauma Research Consortium. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05143476, a study of Humerus Fractures, has completed, sponsored by Major Extremity Trauma Research Consortium.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To define a serum protein-based diagnostic for the progression and failure of fracture healing, through the identification of a set of serum proteins that appear at early times of biological healing and show a specific correlation with later radiological and functional signs used to define delayed healing and non-union.
Primary Outcome
The primary outcome for the assessment of fracture healing will be assessed by gross motion and mRUST (modified radiograph union score) score greater than or equal to 6. mRUST score ranges from 4-16 where score greater than or equal to 6 is considered as the predictors of progression to union.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-06-26 |
| Est. Completion | 2024-10-28 |
What the finished NCT05143476 record still lists
NCT05143476 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 1 condition, with Humerus Fractures appearing as the primary indexed condition, and to 0 interventions.
NCT05143476 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05143476 about?
NCT05143476 is a clinical study titled "Serum-Protein-Based Indices for the Progression of Fracture Healing and Nonunion". To define a serum protein-based diagnostic for the progression and failure of fracture healing, through the identification of a set of serum proteins that appear at early times of biological healing and show a specific correlation with later radiological and functional signs used to define delayed h...
What is the current status of trial NCT05143476?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2021-06-26. Estimated completion is 2024-10-28.
What conditions does trial NCT05143476 study?
This clinical trial studies the following conditions: Humerus Fractures.
Who is sponsoring clinical trial NCT05143476?
This trial is sponsored by Major Extremity Trauma Research Consortium, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143476 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Humerus Fractures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI